StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Alexion (ALXN) to See Releif Rally on ALXN-1210 Results - BMO
March 15, 2018 8:57 AM
BMO Capital analyst M. Ian Somaiya expects shares of Alexion Pharmaceuticals (NASDAQ: ALXN) trade higher as investors breathe a sigh ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Alexion Pharmaceuticals (ALXN) PT Raised to $156 at Nomura/Instinet
March 15, 2018 1:45 PM
Alexion Pharmaceuticals (ALXN) PT Raised to $160 at Baird
March 15, 2018 12:14 PM
Alexion Pharmaceuticals (ALXN) PT Raised to $151 at Raymond James
March 15, 2018 12:13 PM
RBC Sees 10-15% Move in Alexion Pharma (ALXN) Following ALXN-1210 Results
March 15, 2018 9:41 AM
JPMorgan Reiterates Overweight on Alexion Pharma (ALXN) Following Phase 3 Results
March 15, 2018 9:06 AM
S&P falls for fourth day as Mueller subpoena weighs
March 15, 2018 7:47 AM
Alexion (ALXN) Reports Positive Top-Line Results Showing Successful Phase 3 Study of ALXN1210 in Complement Inhibitor Treatment-Naive Patients with PNH
March 15, 2018 6:31 AM
Alexion Announces Positive Top-Line Results Showing Successful Phase 3 Clinical Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
March 15, 2018 6:30 AM
